Details for Patent: 10,201,584
Which drugs does patent 10,201,584 protect, and when does it expire?
Patent 10,201,584 protects VIEKIRA XR and is included in one NDA.
Summary for Patent: 10,201,584
| Title: | Compositions and methods for treating HCV |
| Abstract: | This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents. |
| Inventor(s): | Christine A. Collins, Daniel E. Cohen, Gennadiy Koev, Preethi Krishnan, Tami J. Pilot-Matias |
| Assignee: | AbbVie Inc |
| Application Number: | US14/247,975 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,201,584
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | 10,201,584 | ⤷ Start Trial | TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
